APA (7th ed.) Citation

Spiess, B., Rinaldetti, S., Naumann, N., Galuschek, N., Kossak-Roth, U., Wuchter, P., . . . Seifarth, W. (2019). Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLOS ONE, 14(3), . https://doi.org/10.1371/journal.pone.0214305

Chicago Style (17th ed.) Citation

Spiess, Birgit, et al. "Diagnostic Performance of the Molecular BCR-ABL1 Monitoring System May Impact on Inclusion of CML Patients in Stopping Trials." PLOS ONE 14, no. 3 (2019). https://doi.org/10.1371/journal.pone.0214305.

MLA (9th ed.) Citation

Spiess, Birgit, et al. "Diagnostic Performance of the Molecular BCR-ABL1 Monitoring System May Impact on Inclusion of CML Patients in Stopping Trials." PLOS ONE, vol. 14, no. 3, 2019, https://doi.org/10.1371/journal.pone.0214305.